<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Clofarabine is a second-generation <z:chebi fb="0" ids="26394">purine nucleoside</z:chebi> analogue </plain></SENT>
<SENT sid="1" pm="."><plain>It works mainly by inhibiting <z:chebi fb="0" ids="26561">ribonucleotide</z:chebi> reductase and incorporating into DNA </plain></SENT>
<SENT sid="2" pm="."><plain>Clofarabine has shown efficacy in selected pediatric <z:hpo ids='HP_0001909'>leukemias</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>It has also shown significant efficacy alone and in combination with other drugs in treating adult myeloid <z:hpo ids='HP_0001909'>leukemias</z:hpo> and high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Further, there is significant promise for clofarabine in the treatment of older patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> who are unlikely to benefit from standard induction chemotherapy due to unfavorable baseline prognostic factors </plain></SENT>
<SENT sid="5" pm="."><plain>An oral formulation of clofarabine is also currently under development </plain></SENT>
</text></document>